Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.
Emulate, a US-based biotechnology developer spun out of Harvard University, raised $82m in a series E round led Northpond Ventures on Tuesday.
Perceptive Advisors also contributed funding, bringing the company’s total capital to almost $225m.
Emulate is developing in vitro on-a-chip models of human organs that replicate their function, in order to aid research in human response to drugs.
In addition to potentially accelerating the drug discovery process, the technology is set to benefit from anticipated changes to regulation around animal testing.
Proceeds from the round will be used to scale up research and development for new models related to tumours and immunology, among other areas. Emulate is also partnering two new distributors in the Asia Pacific region to expand its reach.
The company had secured $36m in a 2018 series C round led by Founders Fund with participation from ALS Investment Fund, SciFi VC,…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
